ClinicalTrials.gg

Program

CKD-383

A development code. Also written as “CKD-383 0.5/10/1000mg”, “CKD-383 0.5/25/1000mg” and “CKD-383 0.25/12.5/1000mg”.

Its studies are mostly in Diabetes Mellitus, Type 2, led by Chong Kun Dang Pharmaceutical.

Furthest: phase 1, since Mar 11, 202110 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chong Kun Dang Pharmaceutical101 open or runningphase 1since Mar 11, 2021Mar 11, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 11, 2021First study: phase 1 study in Type2 Diabetes MellitusFirst studyNCT04810676 · 27 enrolled · Korea, Republic of
  2. Apr 5, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05816759 · 32 enrolled · Korea, Republic of
  3. Jun 1, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05897216 · 30 enrolled · Korea, Republic of
  4. Jun 13, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06483243 · 45 enrolled · Korea, Republic of
  5. Jul 1, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06492655 · 28 planned
  6. Nov 17, 20242 phase 1 studies in Diabetes Mellitus, Type 2NCT06695598, NCT06695572
  7. Dec 14, 20253 phase 1 studies in Diabetes Mellitus, Type 2NCT07304726, NCT07304700, NCT07304687

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07304726Diabetes Mellitus, Type 2 · South Korea1CompletedNov 9, 202530
NCT07304700Diabetes Mellitus, Type 2 · South Korea1CompletedNov 7, 202530
NCT07304687Diabetes Mellitus, Type 2 · South Korea1CompletedNov 3, 202531
NCT06695598Diabetes Mellitus, Type 2 · Korea, Republic of1CompletedDec 8, 202430
NCT06695572Diabetes Mellitus, Type 2 · Korea, Republic of1CompletedDec 7, 202430
NCT06492655Diabetes Mellitus, Type 21Not yet recruitingAug 1, 202428
NCT06483243Diabetes Mellitus, Type 2 · Korea, Republic of1CompletedApr 29, 202445
NCT05897216Diabetes Mellitus, Type 2 · Korea, Republic of1CompletedJul 23, 202330
NCT05816759Diabetes Mellitus, Type 2 · Korea, Republic of1CompletedJun 4, 202332
NCT04810676Type2 Diabetes Mellitus · Korea, Republic of1CompletedMay 20, 202127

How it is read

Names in the registry

  • “CKD-383”, 5 entries
  • “CKD-383 0.5/10/1000mg”, 1 entry
  • “CKD-383 0.5/25/1000mg”, 1 entry
  • “CKD-383 0.25/12.5/1000mg”, 1 entry
  • “CKD-383(Fed)”, 1 entry

Codes read as this program: CKD383.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
CKD-383 (Chong Kun Dang Pharmaceutical): development program | ClinicalTrials.gg